South Korea Resumes A/H1N1 Vaccine Talks With GSK, Novartis, Sanofi-Aventis, Baxter, CSL
This article was originally published in PharmAsia News
Executive Summary
SEOUL - One month after South Korea's Ministry for Health, Welfare and Family Affairs failed to select a company to provide A/H1N1 vaccines at what it considered a "reasonable price," the ministry reopened talks with Baxter International, GlaxoSmithKline, Novartis, CSL of Australia and Sanofi-Aventis to calm mounting public pressure to secure the vaccines